Processing...
Clinical Trials for Melanoma
Search
Search
There are 183 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
183 trials meet filter criteria.
Sort by:
HealthScout AI summary: Enrolls adults with unresectable/metastatic melanoma progressing after PD‑1/PD‑L1 therapy and other checkpoint inhibitor–responsive solid tumors for AB821 monotherapy, an IV CD8‑IL21 fusion immunotherapy that selectively activates IL‑21 signaling in CD8+ T cells to enhance cytotoxicity and T‑cell memory. Patients must have ECOG 0–1 and adequate organ function; key exclusions include active autoimmune disease requiring treatment, untreated/unstable CNS metastases, significant cardiovascular disease, chronic immunosuppression, and prior IL‑21–based therapy.
ClinicalTrials.gov ID: NCT07027488
HealthScout AI summary: Enrolling adults (and ≥12 in one cohort) with unresectable stage III/IV melanoma that has progressed after anti–PD-1/PD-L1 therapy (and after BRAF±MEK for V600-mutant), excluding ocular or active CNS disease and >2 prior systemic lines. Intratumoral KB707, an oncolytic HSV-1 engineered to express IL-12 and IL-2, is given with checkpoint blockade (Opdualag or pembrolizumab) to enhance local/systemic antitumor immunity.
ClinicalTrials.gov ID: NCT05970497
HealthScout AI summary: Adults with ECOG 0–1 and measurable advanced/metastatic solid tumors (broad tumor types) receive intramuscular mRNA-4106 monotherapy dose escalation; a separate cohort enrolls treatment‑naive unresectable/metastatic melanoma for mRNA-4106 combined with nivolumab/relatlimab. mRNA-4106 is a lipid‑nanoparticle mRNA vaccine encoding multiple shared tumor-associated antigens to prime/boost tumor‑specific T cells; the combo leverages PD‑1/LAG‑3 blockade.
ClinicalTrials.gov ID: NCT06880549
HealthScout AI summary: Adults with unresectable stage III/IV cutaneous melanoma that progressed during or within 6 months of prior anti–PD‑1/PD‑L1 therapy receive dapansutrile (OLT1177), an oral NLRP3 inflammasome inhibitor blocking caspase‑1–mediated IL‑1β/IL‑18 maturation, with pembrolizumab 200 mg IV q3w after a 14‑day dapansutrile lead-in. Excludes ocular/mucosal melanoma, active CNS disease (unless treated/stable), significant autoimmune disease, and active infections; ECOG 0–2 required.
ClinicalTrials.gov ID: NCT04971499
HealthScout AI summary: Adults with advanced solid tumors driven by MAPK pathway alterations, including cohorts for NRAS‑mutant melanoma, BRAF‑altered melanoma/other tumors, KRAS/NRAS‑mutant non‑melanoma cancers, and BRAF‑altered glioma, receive once‑daily oral NST‑628. NST‑628 is an investigational, brain‑penetrant pan‑RAF/MEK molecular glue that stabilizes inactive RAF–MEK complexes to block MEK/ERK signaling; prior BRAF/MEK inhibitor exposure is excluded in expansion cohorts.
ClinicalTrials.gov ID: NCT06326411
HealthScout AI summary: Adults with unresectable stage III/IV melanoma (ECOG 0–1), including PD‑1–naïve, previously treated, or PD‑1–refractory cohorts, receive nivolumab plus hydroxychloroquine (an autophagy/lysosomal inhibitor) or nivolumab/ipilimumab plus hydroxychloroquine. Aims include defining HCQ dose with PD‑1/CTLA‑4 blockade and assessing response to nivolumab+HCQ, with key exclusions for active severe autoimmune disease, unstable CNS disease, and significant comorbidities.
ClinicalTrials.gov ID: NCT04464759
HealthScout AI summary: Adults with metastatic or unresectable BRAF V600–mutant melanoma who are stable on or have progressed after prior BRAF/MEK therapy receive standard dabrafenib/trametinib or encorafenib/binimetinib with added nilotinib. Nilotinib (a BCR-ABL/c-KIT/PDGFR tyrosine kinase inhibitor) is dose-escalated to assess safety, pharmacokinetics, and preliminary activity of this triplet strategy; treated, stable brain metastases allowed.
ClinicalTrials.gov ID: NCT04903119
HealthScout AI summary: Adults with measurable, biopsy-accessible stage III (macroscopic nodal) or stage IV melanoma, ECOG 0–1, and no prior PD‑1/PD‑L1 or CTLA‑4 therapy receive ipilimumab plus nivolumab combined with CBL0137, a non-genotoxic DNA intercalator that traps FACT to activate p53 and suppress NF‑κB/HSF1/MYC. Excludes active autoimmune disease or need for immunosuppression; serial biopsies and blood draws required.
ClinicalTrials.gov ID: NCT05498792
HealthScout AI summary: Adults with unresectable stage III–IV melanoma (ECOG 0–2), including PD-1–naïve metastatic patients or those with stable/partial response on ongoing PD-1 after ≥12 weeks and prior adjuvant checkpoint or BRAF/MEK allowed; excludes active diabetes requiring meds, active CNS disease, significant immunosuppression, or autoimmune disease needing systemic therapy. Patients receive pembrolizumab alone or pembrolizumab plus metformin (AMPK activator/mitochondrial complex I inhibitor aimed at reversing T-cell metabolic insufficiency) to assess immunometabolic and clinical benefit.
ClinicalTrials.gov ID: NCT03311308
HealthScout AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) after standard therapy failure; phase 1 tests oral GIM‑531 monotherapy (including NSCLC, TNBC, platinum‑resistant ovarian, and AKT3‑altered tumors), and phase 2 treats melanoma, NSCLC, or RCC that progressed on anti‑PD‑1 with continued anti‑PD‑1 plus GIM‑531. GIM‑531 is a first‑in‑class, Treg‑selective small‑molecule inhibitor linked to AKT3/PI3K–AKT pathway modulation to suppress Tregs and potentially restore antitumor immunity.
ClinicalTrials.gov ID: NCT06425926